资料显示，药师帮股份有限公司成立于2015年,是中国院外医药产业最大的数字化综合服务平台。药师 帮致力于用数字化赋能院外医药市场的参与者,包括药企、药品分销商、药店及基层医疗机构,努力以安 全高效的方式将医药健康产品及服务带给下游,使用户都能以公平且透明的价格轻松获得大量、全面且 有品质保证的药品。药师帮以让好医好药普惠可及为使命,驱动医疗健康生态系统整体效率的提升。通 过深耕基层市场,药师帮积累了强大的数据能力,构建并不断完善业务模式,以满足院外医药市场数字化日 益增长的需求。截至2024年,药师帮覆盖49.1万家药店及33万家基层医疗机构,渗透全国98.9%的县域和 91.2%的乡镇,其中月均活跃买家达到43.3万个,建立起国内最大的数字化医药交易与服务网络。 大事提醒 2025年6月5日，公司以每股9.86-9.98港元回购6万股,回购金额59.56万港元 6月6日，截至港股收盘，恒生指数下跌0.48%，报23792.54点。药师帮（09885.HK）收报10.88港元/ 股，上涨8.37%，成交量2032.56万股，成交额2.18亿港元，振幅13.84%。 最近一个月来，药师帮累计涨幅42.12%，今 ...

智通财经6月6日电，一款能让失明动物恢复可见光视觉能力，甚至获得感知红外线能力的视觉假体在实 验室诞生。记者从复旦大学获悉，该校集成电路与微纳电子创新学院周鹏/王水源团队、脑科学研究院 张嘉漪/颜彪团队联合中国科学院上海技术物理研究所胡伟达团队合作开发出全球首款光谱覆盖范围极 广（470-1550nm，从可见光延伸至近红外二区）的视觉假体。该假体无需依赖任何外部设备，仅需微 创手术植入，即可在光照条件下发挥作用。2025年6月6日（北京时间），相关成果以《碲纳米线视网膜 假体增强失明视觉》为题发表于《科学》杂志。 (央视新闻) 能"看见"红外光的"超视觉"假体在实验室诞生 ...

Group 1 - BioLife Solutions, Inc. (BLFS) closed at $22.03, with a 3.2% gain over the past four weeks, and a mean price target of $31.22 indicating a 41.7% upside potential [1] - The average of nine short-term price targets ranges from $30 to $34, with a standard deviation of $1.48, suggesting a low variability among analysts [2] - Analysts are optimistic about BLFS's earnings prospects, with a significant increase in the Zacks Consensus Estimate for the current year by 123.1% [12] Group 2 - The Zacks Rank for BLFS is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - Analysts' agreement on higher earnings estimates is a strong indicator of potential stock price movements, as empirical research shows a correlation between earnings estimate revisions and stock price changes [11] - While price targets are often viewed skeptically, the direction they imply for BLFS appears to be a good guide for potential upside [10][13]

Financial Data and Key Metrics Changes - The company reported a quorum of 92,171,423 shares entitled to vote, with 46,085,712 shares constituting a majority [9] - The voting results indicated that 78,614,062 votes were cast for the ratification of Ernst and Young LLP as auditors, exceeding the majority requirement [17] - The advisory vote on the compensation of named executive officers received 67,000,700 votes in support, also surpassing the majority threshold [17] Business Line Data and Key Metrics Changes - The meeting did not provide specific financial data or performance metrics for individual business lines, focusing instead on governance matters and shareholder voting [3][4] Market Data and Key Metrics Changes - No specific market data or metrics were discussed during the meeting, as the focus was primarily on internal governance and shareholder matters [3][4] Company Strategy and Development Direction and Industry Competition - The company is looking to replenish its equity incentive plan by increasing the share pool by an additional 6,500,000 shares, indicating a focus on retaining talent and incentivizing performance [15][16] - The appointment of Ernst and Young LLP as auditors reflects the company's commitment to maintaining strong financial oversight and governance practices [14] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting, as the session was primarily focused on procedural matters and voting [21][22] Other Important Information - The meeting included the election of three directors, with nominees successfully elected to serve until the 2028 annual meeting [17][20] - The company emphasized that the results of the votes would be filed on Form 8-K and included in the meeting minutes, ensuring transparency [20] Q&A Session Summary Question: Were there any stockholder questions? - There were no stockholder questions during the Q&A session, leading to the official adjournment of the meeting [22][23]

上海优宁维生物科技股份有限公司 关于持股 5%以上股东及其一致行动人 股份变动触及 1%整数倍的公告 证券代码：301166 证券简称：优宁维 公告编号：2025-051 上海创业接力泰礼创业投资中心（有限合伙）、上海泰礼创业投资管理有限公 司－上海含泰创业投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 上海优宁维生物科技股份有限公司（以下简称"公司"或"本公司"）于近日收 到股东上海创业接力泰礼创业投资中心（有限合伙）（以下简称"泰礼投资"）及 其一致行动人上海泰礼创业投资管理有限公司－上海含泰创业投资合伙企业（有 限合伙）（以下简称"含泰投资"）出具的《关于股份减持计划进展的告知函》， 获悉泰礼投资及其一致行动人含泰投资通过集中竞价方式和大宗交易方式合计 减持公司股份1,208,500股，占公司扣除回购专户股份后总股本的1.41%，持股数 量由6,004,188股减少至4,795,688股，泰礼投资及其一致行动人含泰投资合计占公 司扣除回购专户股份后总股本的比例由7.00%下降至 ...

本报记者 王爱静 通讯员 胡杰伟 在数字经济与现代农业深度融合的浪潮中，农行杭州分行以科技金融驱动"质""量"双升，进一步深化乡 村振兴金融服务，创新推出"枇杷贷""茶香贷""水产贷""冻品贷""专业大户贷"等"惠农e贷"系列产品。截 至目前，该分行农户贷款服务已覆盖全杭州1500余个村社，惠及农户超5万户，为农民增收注入强大金 融活力。 在杭州滨富生物科技有限公司智能化养殖基地内，数千万只松子大小的黑水虻幼虫在果蔬残渣中穿梭涌 动，这些曾被视作"垃圾"的有机废弃物，通过生物转化技术，成为具有经济效益和社会效益的"金种 子"。 "从小虫到成虫，短短7天可吃胖4000倍，吃掉比自己重20万倍的厨余垃圾。"杭州滨富生物科技有限公 司负责人杨柱理说，黑水虻幼虫以餐厨垃圾、畜禽粪便、果蔬残渣为食，通过生物降解将高油高盐的有 机垃圾转化为富含蛋白质的虫体和优质有机肥。 "我是'95后'创业者，农行非常支持我们'新农人'和新业态发展。客户经理多次上门服务，一来二去，大 家成了老朋友。"杨柱理说，"在贷款支持下，我们更新了机械设备、优化了产品包装，现在计划开启二 期工程。"杨柱理介绍，二期扩建工程规划新增4500平方米厂房 ...

Core Viewpoint - The Chinese pharmaceutical industry is experiencing a significant transformation, moving from a focus on generic drugs to global innovation, driven by an increase in business development (BD) activities and the emergence of the NewCo model [1][2][5]. Group 1: Market Performance - The Hang Seng Index opened up by 0.74% and the Hang Seng Tech Index by 0.97% on June 5, 2025, indicating positive market sentiment [1]. - The Hang Seng Healthcare ETF (513060) saw a more than 1% increase in intraday trading, with a trading volume exceeding 500 million yuan and a turnover rate of over 6% [1]. - Year-to-date, the Hang Seng Healthcare ETF has risen nearly 40%, reflecting strong market interest [1]. Group 2: Business Development Trends - Since 2024, there has been a notable increase in the volume and value of outbound BD transactions for Chinese innovative drugs, with significant deals in areas such as ADCs, bispecific antibodies, and GLP-1 assets [2]. - The total value of License-out transactions in the innovative drug sector has surged from approximately $11 billion in 2020 to over $51 billion in the first ten months of 2024, showcasing a substantial growth trend [2]. - The increase in transaction size and number is attributed to upgraded transaction structures, enhanced international recognition, and innovative business models like the NewCo model [2]. Group 3: NewCo Model Advantages - The NewCo model addresses challenges such as financing difficulties, monetization issues, and high R&D risks by creating independent companies through partnerships between domestic biotech firms and foreign investors [3][4]. - This model allows for increased financing and monetization channels, enabling independent fundraising while retaining traditional License-out revenue [3]. - It also reduces R&D and commercialization risks by outsourcing high-cost clinical development and market promotion to the NewCo or partners [4]. Group 4: Future Outlook - The pharmaceutical sector is poised for positive development, having completed a transition from old to new growth drivers, with a focus on innovation over generics [5]. - Companies like Heng Rui, Han Sen, and Ke Lun have successfully transformed into innovative players, while outbound capabilities continue to improve [5]. - The rise of AI in healthcare is expected to unlock new growth opportunities, with a recommendation to focus on innovative drugs, outbound strategies, and high-barrier industries [5].

虚拟电厂、新能源车、生物科技概念股活跃；新消费、可控核聚变题材回调。 09:37 A股三大指数盘初转跌，医疗服务、减肥药、乳业板块跌幅居前。 09:35 A股兵装重组概念股盘初走强 东安动力、湖南天雁涨超6%，华强科技、中光学、建设工业、长城军工跟涨。 | 代码 名称 | 涨幅� 现价 | | --- | --- | | 600178 东安动力 | +6.56% 13.15 | | 600698 湖南天雁 | +6.29% 7.27 | | 688151 华强科技 | +4.38% 17.63 | | 002189 中光学 | +3.93% 20.87 | | 002265 建设工业 | +2.34% 20.95 | | 601606 长城军工 | +0.52% 13.55 | 联易融科技-W涨5.81%、连连数字涨5.52%、众安在线涨3.66%。 09:25 A股开盘丨三大股指集体小幅高开 沪指涨0.06%，深成指涨0.08%，创业板指涨0.08%。虚拟电厂、新能源车、生物科技概念股活跃；新消费、可控核聚 变题材回调。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | - ...

Financial Data and Key Metrics Changes - The meeting addressed the formal business of the Annual Meeting of Stockholders, including the election of directors and the ratification of the independent registered public accounting firm [5][12] - Preliminary results indicated that the election of directors and the ratification of Ernst and Young LLP were approved [12][13] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting [16] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [16] Company Strategy and Development Direction and Industry Competition - The board of directors recommended an amendment to the 2020 equity incentive plan to increase the number of shares reserved, which is aimed at attracting and retaining talent [10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [16] Other Important Information - The meeting was held virtually in accordance with company bylaws and Delaware law, and the proxy statement was made available to stockholders prior to the meeting [5][6] Q&A Session Summary - There were no questions submitted during the Q&A session [16]

Summary of IO Biotech (IOBT) Conference Call Company Overview - **Company**: IO Biotech - **Lead Product**: Silenbio (US brand name for IO102, IO103) - **Technology Platform**: TWAN technology platform, focusing on cancer vaccines Core Industry Insights - **Cancer Treatment Focus**: The company is targeting unmet medical needs in cancer treatment, specifically in melanoma, lung, and head and neck cancers - **Market Growth**: - Melanoma market projected to grow to $30 billion by 2030, with a 9% annual growth rate [12] - Lung cancer market projected to reach $60 billion by 2030, with a 10% annual growth rate [23] - Head and neck cancer market expected to grow to $5 billion by 2030, with a 6% annual growth rate [24] Key Product Insights - **Efficacy Data**: - Phase I/II trial showed an 80% overall response rate and a 25.5-month median progression-free survival (PFS) [9] - Phase III trial data expected in Q3 2025, with potential for a Biologics License Application (BLA) filing by the end of 2025 [10] - **Safety Profile**: The product candidates have shown a clear safety profile, allowing patients to remain on treatment longer [5][16] Pipeline Development - **Current Trials**: - Phase III trial with 407 patients randomized to receive either pembrolizumab alone or in combination with IO102 and IO103 [15] - Two Phase II basket trials in first-line solid tumors and perioperative settings [19] - **Future Targets**: - IO112 targeting arginase and IO170 targeting TGF beta are in development, with potential applications in harder-to-treat cancers [21] Market Positioning - **Unmet Needs**: - 50% of melanoma patients do not respond to current standard of care, and 50% of responders experience adverse events [13] - The company aims to address these gaps with its innovative treatment options [12][43] - **Launch Strategy**: Focus on top treaters in both academic and community settings to ensure broad access to the product [18] Competitive Landscape - **Standard of Care**: Current treatments like ipilimumab and nivolumab have a median PFS of 10-11 months, with safety concerns [48] - **Expectations from Key Opinion Leaders**: There is significant excitement and anticipation for the Phase III trial results, with expectations that Silenbio could become the new standard of care if it demonstrates superior efficacy and safety [47][49] Financial Position - **Cash Position**: The company has sufficient cash to support operations through Q2 2026, following recent funding activities [41] Conclusion - **Transformational Potential**: IO Biotech is positioned to potentially transform treatment paradigms in melanoma, lung, and head and neck cancers, with a strong pipeline and promising clinical data [43]